This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RACA Therapeutics Acquisition (RACA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Therapeutics Acquisition Stock (NASDAQ:RACA) Get RACA alerts:Sign Up Key Stats Today's Range N/A50-Day Range$7.67▼$10.4852-Week Range N/AVolumeN/AAverage Volume105,531 shsMarket Capitalization$175.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts. Read More Receive RACA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapeutics Acquisition and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RACA Stock News HeadlinesRoquefort Therapeutics Shifts Focus to Clinical Stage Assets with Strategic AcquisitionSeptember 30, 2025 | msn.comGossamer Bio signs option to acquire Respira TherapeuticsSeptember 25, 2025 | msn.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone. | Porter & Company (Ad)Biogen to buy Massachusetts-based Alcyone TherapeuticsSeptember 18, 2025 | msn.comThe New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks TherapeuticsFebruary 20, 2025 | msn.comBlackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 BillionFebruary 12, 2025 | businesswire.comMaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programsFebruary 12, 2025 | msn.comRoche to Complete $1.5 Billion Acquisition of U.S. Biopharma Company PoseidaJanuary 8, 2025 | msn.comSee More Headlines RACA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Therapeutics Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Therapeutics Acquisition investors own include Churchill Capital Corp IV (CCIV), Gores Holdings IV (GHIV), Qell Acquisition (QELLU), Altimeter Growth (AGCUU), AGBA Acquisition (AGBA), Edoc Acquisition (ADOCU) and ArcLight Clean Transition (ACTCU). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RACA CIKN/A Webwww.researchalliancecorp.com Phone617 778 2500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,041,000Free FloatN/AMarket Cap$175.51 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RACA) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapeutics Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Therapeutics Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RACA Stock Alerts